Daewon Pharmaceutical is joining hands with Celltrion Pharm to target the hypertension drug market.
Daewon Pharmaceutical said on the 6th it signed a domestic co-promotion deal with Celltrion Pharm for three hypertension treatments. Under the agreement, the two companies will jointly sell three products: ▲ Idalbi tablets ▲ Idalbi-clo tablets ▲ Idaldipine tablets.
According to Daewon Pharmaceutical, "Idalbi" is characterized by an excellent T/P ratio, an indicator of how stably blood pressure is controlled throughout the day. Simply put, the effect is maintained evenly all day, meaning less variability in blood pressure. It belongs to the ARB (angiotensin II receptor blocker) class widely used to treat hypertension and is known to lower blood pressure more effectively than valsartan or olmesartan, which have been widely prescribed.
Clinical study results showed that patients given 80 mg of Idalbi saw an average blood pressure reduction 14.3 mmHg greater than those taking 320 mg of valsartan or 40 mg of olmesartan. The drug also showed effects such as reaching target blood pressure in about seven days after dosing, and produced positive results in reducing microalbuminuria, an indicator of declining kidney function.
"Idaldipine" is a fixed-dose combination that combines two ingredients in a single pill. It contains azilsartan medoxomil, which has a strong antihypertensive effect, together with amlodipine, a representative drug in the calcium channel blocker (CCB) class that dilates blood vessels to lower blood pressure. The company said this can reduce the pill burden for patients who previously had to take multiple medications separately.
According to the Korean Society of Hypertension, about 60% of hypertension patients in Korea take two or more blood pressure medications together. Among them, combination prescriptions using an ARB or ACE inhibitor with a CCB account for more than 70% of the total. Daewon Pharmaceutical expects that strengthening its fixed-dose combination lineup in line with this treatment trend will broaden options for patients.
A Daewon Pharmaceutical official said, "We are already delivering results in the chronic disease treatment segment," and added, "Based on our proven sales and marketing competitiveness in cardiology, we will also solidify the market position of the 'Idalbi family.'"